U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H29NO10.C6H8O7
Molecular Weight 719.6434
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DAUNORUBICIN CITRATE

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(=O)C4=C(C=CC=C4OC)C3=O)C(O)=C12)C(C)=O)O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5

InChI

InChIKey=VNTHYLVDGVBPOU-QQYBVWGSSA-N
InChI=1S/C27H29NO10.C6H8O7/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t10-,14-,16-,17-,22+,27-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C27H29NO10
Molecular Weight 527.5199
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C6H8O7
Molecular Weight 192.1235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22260166 | https://www.ncbi.nlm.nih.gov/pubmed/7932544 | https://www.ncbi.nlm.nih.gov/pubmed/13146115 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050467s070lbl.pdf

Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically, it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Similar to doxorubicin, daunorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CERUBIDINE

Approved Use

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Launch Date

3.14409615E11
Primary
CERUBIDINE

Approved Use

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Launch Date

3.14409615E11
Primary
CERUBIDINE

Approved Use

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Launch Date

3.14409615E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
26 μg/mL
44 mg/m² 1 times / 2 days multiple, intravenous
dose: 44 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: Cytarabine
DAUNORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
637 μg × h/mL
44 mg/m² 1 times / 2 days multiple, intravenous
dose: 44 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: Cytarabine
DAUNORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
31.5 h
44 mg/m² 1 times / 2 days multiple, intravenous
dose: 44 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: Cytarabine
DAUNORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
DAUNORUBICIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources: Page: p.573, 575
unhealthy, 10
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 10
Sex: M+F
Population Size: 6
Sources: Page: p.573, 575
DLT: Neutropenia, Leucopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 100%)
Leucopenia (grade 4, 100%)
Thrombocytopenia (grade 4, 16.7%)
Anemia (grade 4, 16.7%)
Sources: Page: p.573, 575
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources: Page: p.573, 575
unhealthy, 10
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 10
Sex: M+F
Population Size: 6
Sources: Page: p.573, 575
DLT: Neutropenia, Leucopenia...
Disc. AE: Cardiac failure...
Dose limiting toxicities:
Neutropenia (grade 4, 100%)
Leucopenia (grade 4, 50%)
AEs leading to
discontinuation/dose reduction:
Cardiac failure (grade 5, 16.7%)
Sources: Page: p.573, 575
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources: Page: p.11
unhealthy, 27-87
n = 239
Health Status: unhealthy
Condition: Ovarian Cancer
Age Group: 27-87
Sex: M+F
Population Size: 239
Sources: Page: p.11
Disc. AE: Skin toxicity...
AEs leading to
discontinuation/dose reduction:
Skin toxicity (4.2%)
Sources: Page: p.11
20 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 20 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 20 mg/m2, 1 times / 2 weeks
Sources: Page: p.11
unhealthy, 38.7
n = 705
Health Status: unhealthy
Condition: AIDS-related Kaposi’s sarcoma
Age Group: 38.7
Sex: M+F
Population Size: 705
Sources: Page: p.11
Disc. AE: Skin eruption...
AEs leading to
discontinuation/dose reduction:
Skin eruption (0.9%)
Sources: Page: p.11
80 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 80 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 80 mg/m2, 1 times / 3 weeks
Co-administed with::
vincristine, i.v(1.4 mg/m2, day 1)
dexamethasone, p.o(40 mg/day, days 1–4 and 9–12)
Sources: Page: p.795
unhealthy, 60
n = 3
Health Status: unhealthy
Condition: Multiple myeloma
Age Group: 60
Sex: M+F
Population Size: 3
Sources: Page: p.795
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Co-administed with::
vincristine, i.v(1.4 mg/m2, day 1)
dexamethasone, p.o(40 mg/day, days 1–4 and 9–12)
Sources: Page: p.795
unhealthy, 60
n = 3
Health Status: unhealthy
Condition: Multiple myeloma
Age Group: 60
Sex: M+F
Population Size: 3
Sources: Page: p.795
DLT: Acute diverticular perforation...
Dose limiting toxicities:
Acute diverticular perforation
Sources: Page: p.795
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Co-administed with::
dexamethasone, p.o(40 mg/day, days 1–4)
Sources: Page: p.2648
unhealthy, 63
n = 38
Health Status: unhealthy
Condition: Multiple myeloma
Age Group: 63
Sex: M+F
Population Size: 38
Sources: Page: p.2648
Disc. AE: Ejection fraction decreased, Prolonged neutropenia...
Other AEs: Granulocytopenia, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Ejection fraction decreased (5.3%)
Prolonged neutropenia (2.6%)
Other AEs:
Granulocytopenia (grade 4, 21%)
Thrombocytopenia (grade 4, 8%)
Febrile neutropenia (grade 4, 11%)
Sources: Page: p.2648
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Ovarian Cancer
Sources: Page: p.1
Disc. AE: Infusion related reaction, Myelosuppression...
AEs leading to
discontinuation/dose reduction:
Infusion related reaction (acute)
Myelosuppression (severe)
Cardiotoxicity
Congestive heart failure
Hepatic impairment
Reaction anaphylactic anaphylactoid (grade 3-5)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Leucopenia grade 4, 100%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources: Page: p.573, 575
unhealthy, 10
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 10
Sex: M+F
Population Size: 6
Sources: Page: p.573, 575
Neutropenia grade 4, 100%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources: Page: p.573, 575
unhealthy, 10
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 10
Sex: M+F
Population Size: 6
Sources: Page: p.573, 575
Anemia grade 4, 16.7%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources: Page: p.573, 575
unhealthy, 10
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 10
Sex: M+F
Population Size: 6
Sources: Page: p.573, 575
Thrombocytopenia grade 4, 16.7%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources: Page: p.573, 575
unhealthy, 10
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 10
Sex: M+F
Population Size: 6
Sources: Page: p.573, 575
Neutropenia grade 4, 100%
DLT
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources: Page: p.573, 575
unhealthy, 10
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 10
Sex: M+F
Population Size: 6
Sources: Page: p.573, 575
Leucopenia grade 4, 50%
DLT
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources: Page: p.573, 575
unhealthy, 10
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 10
Sex: M+F
Population Size: 6
Sources: Page: p.573, 575
Cardiac failure grade 5, 16.7%
Disc. AE
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources: Page: p.573, 575
unhealthy, 10
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 10
Sex: M+F
Population Size: 6
Sources: Page: p.573, 575
Skin toxicity 4.2%
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources: Page: p.11
unhealthy, 27-87
n = 239
Health Status: unhealthy
Condition: Ovarian Cancer
Age Group: 27-87
Sex: M+F
Population Size: 239
Sources: Page: p.11
Skin eruption 0.9%
Disc. AE
20 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 20 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 20 mg/m2, 1 times / 2 weeks
Sources: Page: p.11
unhealthy, 38.7
n = 705
Health Status: unhealthy
Condition: AIDS-related Kaposi’s sarcoma
Age Group: 38.7
Sex: M+F
Population Size: 705
Sources: Page: p.11
Acute diverticular perforation DLT, Disc. AE
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Co-administed with::
vincristine, i.v(1.4 mg/m2, day 1)
dexamethasone, p.o(40 mg/day, days 1–4 and 9–12)
Sources: Page: p.795
unhealthy, 60
n = 3
Health Status: unhealthy
Condition: Multiple myeloma
Age Group: 60
Sex: M+F
Population Size: 3
Sources: Page: p.795
Prolonged neutropenia 2.6%
Disc. AE
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Co-administed with::
dexamethasone, p.o(40 mg/day, days 1–4)
Sources: Page: p.2648
unhealthy, 63
n = 38
Health Status: unhealthy
Condition: Multiple myeloma
Age Group: 63
Sex: M+F
Population Size: 38
Sources: Page: p.2648
Ejection fraction decreased 5.3%
Disc. AE
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Co-administed with::
dexamethasone, p.o(40 mg/day, days 1–4)
Sources: Page: p.2648
unhealthy, 63
n = 38
Health Status: unhealthy
Condition: Multiple myeloma
Age Group: 63
Sex: M+F
Population Size: 38
Sources: Page: p.2648
Febrile neutropenia grade 4, 11%
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Co-administed with::
dexamethasone, p.o(40 mg/day, days 1–4)
Sources: Page: p.2648
unhealthy, 63
n = 38
Health Status: unhealthy
Condition: Multiple myeloma
Age Group: 63
Sex: M+F
Population Size: 38
Sources: Page: p.2648
Granulocytopenia grade 4, 21%
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Co-administed with::
dexamethasone, p.o(40 mg/day, days 1–4)
Sources: Page: p.2648
unhealthy, 63
n = 38
Health Status: unhealthy
Condition: Multiple myeloma
Age Group: 63
Sex: M+F
Population Size: 38
Sources: Page: p.2648
Thrombocytopenia grade 4, 8%
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Co-administed with::
dexamethasone, p.o(40 mg/day, days 1–4)
Sources: Page: p.2648
unhealthy, 63
n = 38
Health Status: unhealthy
Condition: Multiple myeloma
Age Group: 63
Sex: M+F
Population Size: 38
Sources: Page: p.2648
Cardiotoxicity Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Ovarian Cancer
Sources: Page: p.1
Congestive heart failure Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Ovarian Cancer
Sources: Page: p.1
Hepatic impairment Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Ovarian Cancer
Sources: Page: p.1
Infusion related reaction acute
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Ovarian Cancer
Sources: Page: p.1
Reaction anaphylactic anaphylactoid grade 3-5
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Ovarian Cancer
Sources: Page: p.1
Myelosuppression severe
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Ovarian Cancer
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 203 uM]
yes [Ki 49.4 uM]
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Myocardial injury produced by antineoplastic drugs.
1975
Endomyocardial fibrosis associated with daunorubicin therapy.
1976 Aug
Letter: Pericarditis in a case of early daunorubicin cardiomyopathy.
1976 Sep
Bradycardia due to anthracyclines.
1992 Oct 3
High density lipoprotein catabolism in primary cultured hepatocytes from daunomycin-induced nephrotic rats.
1999
All-trans retinoic acid-induced multiple mononeuropathies.
1999 Apr
IGF-I in experimental daunorubicin-induced cardiomyopathy in rabbits.
1999 Mar
Stress-induced gastric lesion formation is prevented in rats with daunomycin-induced nephrosis.
1999 Oct
Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
1999 Oct 15
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
2000
Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells.
2000 Apr 1
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
2000 Aug 1
Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
2000 Aug 1
Focal degradation of cytoplasmic organelles in cardiomyocytes during regenerative and plastic myocardial insufficiency.
2000 Dec
Chest and back pain associated with a six-hour infusion of liposomal daunorubicin.
2000 Jun
Anthracycline induced cardiomyopathy: successful treatment with angiotensin converting enzyme inhibitors.
2000 May
Regulation of phospholipase D activity and ceramide production in daunorubicin-induced apoptosis in A-431 cells.
2000 Nov 15
Daunorubicin attenuates tumor necrosis factor-alpha-induced biosynthesis of plasminogen activator inhibitor-1 in human umbilical vein endothelial cells.
2001 Apr 23
Ultrastructural changes in cardiomyocyte mitochondria during regenerative and plastic insufficiency of the myocardium.
2001 Feb
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
2001 Feb
Down-regulation of catalase gene expression in the doxorubicin-resistant AML subline AML-2/DX100.
2001 Feb 16
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome.
2001 Jul
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
2001 Jul 1
[Characteristics of mutants of Streptomyces peucetius subsp. caesius ATCC 27952 resistant to anthracycline antibiotics].
2001 Jul-Aug
Alterative and plastic insufficiency of cardiomyocytes: isoproterenol-induced damage to myocardium during anthracycline cardiomyopathy.
2001 Jun
NTPase/helicase of Flaviviridae: inhibitors and inhibition of the enzyme.
2002
Effects of dietary lipids on daunomycin-induced nephropathy in mice: comparison between cod liver oil and soybean oil.
2002 Apr
Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis.
2002 Dec
Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
2002 Feb
Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma.
2002 Feb
[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
2002 Jul-Aug
Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells.
2002 Nov
High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia.
2003
Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia.
2003 Jul
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand.
2003 Jun
[Successful treatment after acute promyelocytic leukemia (APL) syndrome of relapsed API with arsenic trioxide].
2003 Mar
Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy.
2003 Nov
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.
2003 Oct
Human intestinal absorption of imidacloprid with Caco-2 cells as enterocyte model.
2004 Jan 1
Patents

Sample Use Guides

Usual Adult Dose for Acute Nonlymphocytic Leukemia: Under 60 years of age: 45 mg/m2 IV over 2 to 5 minutes once a day on days 1, 2, and 3 for the first course and on days 1 and 2 for subsequent courses) with cytosine arabinoside (ara-C) intravenously once a day (usually for 7 days for the first course and 5 days for subsequent courses) as remission induction therapy.
Route of Administration: Intravenous
In order to determine the viability of HL-60, K562, THP-1, and HEK293T cells, they were trypsinized, counted, and seeded into 96-well plates and were treated with serial dilutions (0.0001, 0.001, 0.01, 0.1, 1 mkM) of DNR (Daunorubicin). Cell viability was determined 48 h after DNR treatment using the luminescent cell viability assay (Promega) through luminescence testing by BMG NOVOstar machine.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:24:21 UTC 2023
Edited
by admin
on Wed Jul 05 23:24:21 UTC 2023
Record UNII
5L84T2Z6NP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DAUNORUBICIN CITRATE
MART.   ORANGE BOOK   WHO-DD  
Common Name English
Daunorubicin Citrate [WHO-DD]
Common Name English
DAUNORUBICIN LIPOSOMAL
Brand Name English
5,12-NAPHTHACENEDIONE, 8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-, (8S,10S)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)
Common Name English
DAUNORUBICIN CITRATE [ORANGE BOOK]
Common Name English
5,12-NAPHTHACENEDIONE, 8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-, (8S,10S)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1) (SALT)
Common Name English
DAUNOXOME
Brand Name English
DAUNORUBICIN CITRATE LIPOSOME
VANDF  
Common Name English
DAUNORUBICIN CITRATE LIPOSOME [VANDF]
Common Name English
DAUNORUBICIN CITRATE [MART.]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 73693
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
FDA ORPHAN DRUG 266508
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
FDA ORPHAN DRUG 393413
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
NCI_THESAURUS C1594
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
EU-Orphan Drug EU/3/08/585
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID20190659
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
PRIMARY
RXCUI
221087
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
PRIMARY
CAS
371770-68-2
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
PRIMARY
DRUG BANK
DBSALT001476
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
PRIMARY
ChEMBL
CHEMBL178
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
PRIMARY
NCI_THESAURUS
C47471
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
PRIMARY
SMS_ID
100000086576
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
PRIMARY
PUBCHEM
9961878
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
PRIMARY
FDA UNII
5L84T2Z6NP
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
PRIMARY
RXCUI
1364321
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
ALTERNATIVE
RXCUI
214468
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
ALTERNATIVE
EVMPD
SUB22734
Created by admin on Wed Jul 05 23:24:21 UTC 2023 , Edited by admin on Wed Jul 05 23:24:21 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC